Atlas Trials

A Study of Treatment Success in Changing From Olanzapine to Long-acting Injectable Risperidone (RISPERDAL® CONSTA™)

Clinical trial NCT00216632 · COMPLETED

Trial details

NCT number
NCT00216632
Sponsor
Janssen Pharmaceutica N.V., Belgium
Status
COMPLETED
Phase
Phase 4
Study type
INTERVENTIONAL
SchizophreniaPsychotic Disorders
Start date
2005-03-01
Primary completion
2007-07-01
Enrollment
99

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.